Kornimate/medical-research-clean huggingface dataset:
brain network stimulation for chronic low back pain.

Conditions: Chronic Low Back Pain (CLBP)

Summary: this study looks at the non-invasive brain stimulation technique in people with chronic low back pain to see: * how effective non-invasive brain stimulation is at improving pain intensity in people with chronic low back pain? * how safe non-invasive brain stimulation is and what side effects there may be? * what study participants think of the study procedures and of the non-invasive brain stimulation as a treatment technique for chronic low back pain. participants will be assigned to receive either active brain stimulation group or sham stimulation group randomly. participants will be required to attend a total of twelve treatment sessions (approximately 1-hour each, three sessions per week, for four consecutive weeks). assessments will be done at baseline (in the week 0), immediately post-completion of the intervention (in the week 5), and at the follow-up of one-month (in the week 8), three-months (in the week 16) and six-months (in the week 28) post-completion of intervention.


Eligibility criteria:
inclusion criteria: * age between 18 to 75 years on the day of screening * pain in the lower back (region between 12th rib and gluteal fold) with or without accompanying leg pain that occurs for at least half the days in the last six months * an average pain intensity of ≥4 on the 11-point nprs (0=no pain to 10=pain as bad as you can imagine) in the week prior to enrolment * a disability score of ≥5 on roland-morris disability questionnaire (rmdq). exclusion criteria: * known or suspected serious spinal pathology (fracture; lumbar canal stenosis, malignant, inflammatory or infective diseases of the spine; cauda equina syndrome or widespread neurological disorder) * suspected or confirmed pregnancy or less than six months post-partum * inflammatory disorders * auto-immune conditions * recent soft tissue injuries of the back in the last 3 months * recent steroid injections to the back in the past 3 months * recent spinal surgery in the past 12 months or scheduled/waiting for any major surgical procedures during the treatment or follow-up period or underwent rhizotomy or any neurosurgical procedures * history of neurological conditions, or psychiatric disorders (except depression and anxiety disorders) * history of cancer, or currently receiving/scheduled for receiving therapy for cancer * cognitive impairments (dementia, alzheimer's disease; indicated by a total score of 24 or below on mini-mental state examination) * alcohol or substance abuse * history of epilepsy or seizures * presence of any electronic implants (e.g., pacemaker), metal implant in the body (particularly head and neck), or spinal cord stimulator.

Keywords: chronic low back pain brain stimulation transcranial infraslow grey noise stimulation randomised controlled trial
success of intraoperative cholangiography

Conditions: Cholecystolithiasis; Choledocholithiasis

Summary: the purpose of the present study was to evaluate the success of routine use of intraoperative cholangiography (ioc ) and to examine the factors that are hindering the performance of intraoperative c-arm cholangiography.

from january 2018 to august 2018 all consecutive elective and emergency cholecystectomies performed were entered in a prospective database. ioc has been instructed to be performed routinely when feasible during cholecystectomy since 1998. all elective operations were performed either by residents or specialist surgeons. for this study the investigators collected the radiation exposure values from exposure and pulsed fluoroscopy. fluoroscopy time (s) was recorded.the operating surgeon was asked to fulfill a questionnaire directly after the cholecystectomy. the technical success and reasons for possible deferral of ioc were documented.patient data from unsuccessful or deferred cholangiography cases was checked 6 months after cholecystectomy for possible symptomatic residual choledocholithiasis.laparoscopic cholecystectomies were performed both by residents and specialist surgeons. ethics: the study was approved by the hospital administration.

Eligibility criteria:
inclusion criteria: * all consecutive cholecystectomy patients during january 2018 to august 2018 exclusion criteria: * none

Keywords: c arm cholangiography cholecystectomy
efficacy and safety of caspofungin for invasive pulmonary aspergillosis underlying chronic obstructive pulmonary disease

Conditions: Invasive Pulmonary Aspergillosis; Chronic Obstructive Pulmonary Disease

Summary: the investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable ipa underlying chronic obstructive pulmonary disease.

recently, there has been increasing appreciation of chronic obstructive pulmonary disease (copd) as an important risk factor of invasive pulmoanry aspergillosis (ipa). however, clinical data on the morbidity and mortality of ipa underlying copd as well as the efficacy and safety of antifungal treatment in such subset of patient population is very limited. in clinical pratice, capofungin is often used as primary antifungal therapy for ipa, especially in patients with impaired renal function. based on this data, the investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable ipa underlying copd.

Eligibility criteria:
inclusion criteria: * proven invasive pulmonary aspergillosis * probable invasive pulmonary aspergillosis * hospitalized in respiratory wards * not having received an empirical antifungal therapy for 72h before inclusion exclusion criteria: * a history of allergy to echinocandins * severe renal failure, severe hepatic insufficiency * inadequately treated bacterial infection * documented hiv infection * status of pregnancy or lactation
lidocaine reduces muscle tremor is beneficial for intraoperative recurrent laryngeal nerve monitoring

Conditions: Thyroid Cancer; Neck Cancer; Recurrent Laryngeal Nerve Injuries; Accessory Nerve Injuries; EMG: Repetitive Nerve Stimulation Abnormality

Summary: in recent years, the application of intraoperative recurrent laryngeal nerve monitoring in thyroid surgery has greatly reduced the complications of recurrent laryngeal nerve injury. the use of intraoperative neurological monitoring requires the reduction of the dose of neuromuscular blockade, which often leads to muscle tremors during the application of electrical energy, which affects the fine separation around the muscles. this study explored the effect of local application of lidocaine on reducing muscle tremor during surgery and its optimal dose.

according to the random number method, eligible patients were randomly divided into 2 groups. group a was the conventional surgery group, and group b was the lidocaine group. the operative time for the separation of the sternocleidomastoid muscle from the two groups of patients was analyzed, as well as the length of time for the search for the accessory nerve and the effect of intraoperative nerve monitoring on the emg signal.

Eligibility criteria:
inclusion criteria: * thyroid papillary carcinoma * lateral cervical lymph node metastasis * the diameter of the metastatic lymph nodes is less than 3cm * without internal jugular vein invasion exclusion criteria: * lidocaine allergy sufferers
new technologies to determine carotid plaque vulnerability in patients with significant carotid plaques

Conditions: Carotid Artery Plaque

Summary: the researchers are trying to determine if the characterization of "vulnerable" carotid artery plaques can be accomplished with ultrasound-based methods that look for vessels in the plaque and measure the plaque stiffness.

all participants will receive a one time carotid contrast-enhanced ultrasound (ceus) examination that may take 30-60 minutes. follow up calls will be made to the participants at 6, 12 ,24 and 36 months to ask about occurrence of major adverse cardiovascular events.

Eligibility criteria:
inclusion criteria: * subject has carotid plaque with \> 50% stenosis * subject is able to understand the study procedure and provide informed consent exclusion criteria: * subject is pregnant or breast feeding * subject is unable to provide informed consent * subject has contraindication to the use of the lumason contrast agent.

Keywords: carotid plaque contrast enhanced ultrasound shear wave elastography endarterectomy stenosis
shr-1701 in patients with recurrent/metastatic scchn

Conditions: Squamous Cell Carcinoma of Head and Neck

Summary: this is an open label, single-arm, multi-center, phase ii study of shr-1701 in patients with recurrent/metastatic scchn


Eligibility criteria:
inclusion criteria: 1. histologically confirmed recurrent/metastatic scchn,not include npc 2. subjects failure after 1 lines of platinum based chemotherapy or failure from anti-pd-1/pd-l1 antibody therapy. 3. eastern cooperative oncology group (ecog) performance status of 0 to 1 at trial entry. 4. disease must be measurable with at least 1 uni dimensional measurable lesion by response evaluation criteria in solid tumors (recist) version 1.1. 5. adequate hematological, hepatic and renal function as defined in the protocol other protocol-defined inclusion criteria could apply. exclusion criteria: 1. prior therapy with an anti-pd1, anti-pd-l1, anti-ctla-4 or a tgfb inhibitor. 2. anticancer treatment within 28 days before the first dose of study drug. 3. major surgery within 28 days before start of trial treatment. 4. systemic therapy with immunosuppressive agents within 7 days prior to the first dose of study drug; or use any investigational drug within 28 days before the start of trial treatment. 5. with any active autoimmune disease or history of autoimmune disease. 6. history of immunodeficiency including seropositive for human immunodeficiency virus (hiv), or other acquired or congenital immunedeficient disease, or any active systemic viral infection requiring therapy.

Keywords: shr-1701 phase ii
decrease opioid consumption with intra-venous (iv) acetaminophen after colorectal surgery (dociva)

Conditions: Pain Control Post Colorectal Surgery

Summary: the investigators hypothesis is that use of iv acetaminophen will significantly decrease use of post-operative opioid consumption and enhances recovery after colorectal surgery.

all patients undergoing laparoscopic and open colorectal surgery are randomized to receive either iv acetaminophen or placebo. all patients received an opioid patient controlled anesthesia (pca). iv acetaminophen (1 gram) or placebo is given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge. the investigators primary endpoint is to evaluate opioid consumption during the patient's hospital stay. the investigators secondary endpoints are to evaluate return of gastrointestinal function (rogif), time to diet ordered (ttdo), length of hospital stay (lohs) and occurrence of ileus. pain is measured with the pain visual analog scale score (pvass) at 3, 8, 24 and 48 hours.

Eligibility criteria:
inclusion criteria: * patient undergoing colorectal operation (hartmann's procedure, sigmoidectomy, left hemicolectomy, right hemicolectomy, transverse colectomy, ileocecectomy, colo-colonic anastomosis, colorectal anastomosis, ileo-colonic anastomosis, low anterior resection, or abdominoperineal resection) * age range from 18 to 90 years old * patient providing signed, written informed consent before participation in the study exclusion criteria: * patient younger than 18 years old or older than 90 years old * patient or family is unable to give consent * patient who use opioids or tramadol daily for \>7 days before study medication administration(patient who, in the investigator's opinion, had or was developing opioid tolerance) * patient who had a chronic pain condition or any significant medical disease, laboratory abnormality, or condition that, in the investigator's judgment, could have compromised the subject's welfare, ability to communicate with the study staff, complete study activities, or otherwise restricted study participation * patient who had hypersensitivity to opioids, acetaminophen, or the inactive ingredients of the study medication * patient who had known or suspected history of alcohol or drug abuse or dependence within the previous 1 year * patient who had impaired liver function * patient who had fever within first 48 hours post-operatively and required acetaminophen for fever reduction

Keywords: iv acetaminophen colorectal surgery enhance recovery opioid consumption pain management
a trial of centanafadine efficacy and safety in children with attention-deficit/ hyperactivity disorder (adhd)

Conditions: Attention Deficit/Hyperactivity Disorder

Summary: this trial will be conducted to evaluate the efficacy of centanafadine qd xr versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with adhd. the trial will consist of a screening period, a double-blind treatment period, and follow-up period.


Eligibility criteria:
inclusion criteria: * males and females aged 4 to 12 years (inclusive) at the time of informed consent/assent. * a primary diagnosis of adhd based on dsm-5 diagnosis criteria as confirmed with the mini-kid. * a minimum symptoms total raw score of ≥ 28 on the adhd-rs-5 at baseline for all subjects. * a score of 4 or higher on the cgi-s-adhd at baseline. * subjects aged 4 or 5 years only: has failed adequate psychotherapy or in the investigator's opinion, is severe enough to require pharmacotherapy in the absence of prior psychotherapy. exclusion criteria: * comorbid diagnosis of: tourette's disorder, generalized anxiety disorder that is severe enough to interfere with trial procedures, panic disorder, conduct disorder, psychosis, post-traumatic stress disorder, bipolar disorder, autism spectrum disorder, oppositional defiant disorder that is severe enough to interfere with trial conduct (allowed if it is not the primary focus of treatment), obsessive-compulsive disorder that is severe enough to interfere with trial conduct (allowed if it is not the primary focus of treatment), or mdd with current major depressive episode. * a significant risk of committing suicide based on history and the investigator's clinical judgment, or routine psychiatric status examination, current suicidal behavior, imminent risk of injury to self, active suicidal ideation. a history of suicidal behavior (over the last 6 months). * bmi ≥ 40 kg/m2 or ≤ 5th percentile for age and gender based on us cdc criteria. * has initiated, changed, or discontinued receiving psychological interventions for adhd within the 30 days before the screening visit, or is anticipated to start new treatment during the trial.

Keywords: centanafadine adhd
strategies to maintain cardiac risk control after discharge from cardiovascular risk reduction clinic

Conditions: Diabetes; Dyslipidemia; Hypertension; Coronary Atherosclerosis

Summary: the purpose of this study is to determine whether a combined behavioral and pharmacological intervention provided by a multidisciplinary team will further reduce ldl-c, smoking, bp and hb-a1c in diabetic patients with a1c between 7% and 9% when compared to usual care.


Eligibility criteria:
inclusion criteria: * previous enrollment in cardiovascular risk reduction clinic (crrc) * eligible for crrc discharge: 1. for dm patients: * hba1c \< 7.0 %, * bp \< 130/85 mm hg , and * ldl \< 100 mg/dl; 2. for non-dm patients: * bp \< 140/90 mm hg, and * ldl \< 100 mg/dl; * able and willing to sign informed consent. exclusion criteria: * presence of conditions that might limit long-term compliance (eg, dementia, acute psychiatric decompensation within the previous 6 months, unstable psychiatric disorder); * metastatic disease or terminal illness
comparative effect of clear aligner mandibular advancement and twin block appliances in class ii malocclusion

Conditions: CLASS II DIVISION 1 MALOCCLUSION

Summary: the goal of this retrospective observational study is to compare the effects of clear aligner mandibular advancement (ma) and twin block (tb) appliances in treating class ii malocclusion, a condition where the lower jaw is underdeveloped. the main questions it aims to answer are: 1. does mandibular advancement with clear aligners improve jaw and dental alignment as effectively as twin block appliances? 2. what are the differences in soft tissue changes, such as chin advancement and lip position, between these two treatments? researchers will compare ma and tb appliances to an untreated control group to evaluate their impact on skeletal, dental, and soft tissue outcomes. participants in the study underwent cephalometric analysis (x-ray measurements) both before and after treatment to assess changes in jaw positioning, overbite, and overjet. the study focuses on how each treatment affects facial aesthetics and dental function. participants in the study will: * undergo treatment with either clear aligner mandibular advancement or twin block appliances. * attend follow-up appointments to monitor progress and assess treatment outcomes.

supplementary information for study design it was a retrospective study that collected patients' routine treatment x-rays (before and after treatment) to measure some angular and linear parameters from the x-rays.

Eligibility criteria:
inclusion criteria: * patients who have completed ma or tb treatment at the west china hospital of stomatology orthodontic department. * pretreatment lateral cephalometric radiographs showing cervical vertebral maturation stage (cvsm) ii or iii. * patients in the mixed dentition or early permanent dentition stages. * class ii division 1 malocclusion according to angle's classification * anb angle \&gt; 4°; snb ≤ 78°. * comprehensive medical records and necessary data available pre- and post-treatment. exclusion criteria: * missing teeth, supernumerary teeth, or severe dental malformations affecting function. * poor oral hygiene. * systemic diseases or congenital deformities. * history of dental or maxillofacial trauma. * incomplete or missing records.
risk indicators of sarcoidosis evolution-unified protocol

Conditions: Sarcoidosis, Pulmonary

Summary: the purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.

the purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and biological markers that can be obtained during a clinic visit. primary aim/objective the primary objective of this study is to determine which clinical features measured during a routine clinic visit are risk factors for progression of pulmonary sarcoidosis over the follow-up period in adults with pulmonary sarcoidosis. secondary aim/objectives the secondary objective is to determine if blood biomarkers measured during a routine clinic visit can improve the risk assessment for progression of pulmonary sarcoidosis over the follow-up period. the investigators will measure two types of blood markers to achieve this goal: * clinically available blood markers that are available in most clinical labs * blood proteins and gene expression that reflect interferon inflammation and are not currently available as tests in clinical labs

Eligibility criteria:
inclusion criteria: 1. adults with a diagnosis of sarcoidosis over the age of 18 2. case definition: we will follow the 1999 statement on sarcoidosis published by the american thoracic society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection exclusion criteria: 1. inability to tolerate study procedures as determined by the investigator 2. pregnant or breastfeeding 3. concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. this includes diseases such as common variable immunodeficiency, hiv infection, or autoimmune diseases 4. concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis 5. hematocrit (packed cell volume) \< 25%

Keywords: sarcoid, lung, immune
study of pexidartinib in asian subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is a phase i, non-randomized, open-label, multiple dose study of pexidartinib in asian subjects with advanced solid tumors. the study will be conducted in a dose escalation to assess the safety and tolerability, pharmacokinetics (pk) and pharmacodynamics (pd), and preliminary antitumor activity of pexidartinib.


Eligibility criteria:
inclusion criteria: * age should be ≥ 20 years * subjects must have a pathologically documented solid tumor that has relapsed from, or is refractory to standard treatment, or for which no standard treatment is available * all associated toxicity from previous cancer therapy must have been resolved (to ≤ grade 1) prior to administration of pexidartinib * eastern cooperative oncology group (ecog) score of 0 or 1 * adequate hematologic, hepatic, and renal function tests * adequate treatment washout period before registration defined as: 1. major surgery: ≥ 4 weeks (2 weeks for less invasive surgery, such as colostomy) 2. radiation therapy (eg, whole brain radiotherapy): ≥ 4 weeks (if palliative stereotactic radiation therapy, ≥ 2 weeks) 3. chemotherapy or immunotherapy (including targeted therapy with antibody or small molecule, retinoid therapy, and hormonal therapy): 4 weeks or 5 half-lives of the agent, whichever is shorter (if the regimen has contained nitrosoureas or mitomycin c, ≥ 6 weeks) 4. other investigational drug therapy: ≥ 4 weeks exclusion criteria: * refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would have precluded adequate absorption * previous use of pexidartinib or any biologic treatment targeting colony stimulating factor-1 (csf-1) or the receptor for colony-stimulating factor-1 (csf1r); previous use of oral tyrosine kinase inhibitors, eg, imatinib or nilotinib, is allowed * clinically active primary central nervous system tumors or brain metastasis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms * active or chronic infection with hepatitis c or known positive hepatitis b surface. antigen, or known active or chronic infection with human immunodeficiency virus * a screening fridericia-corrected time between the start of the q wave and the end of the t wave in the heart's electrical cycle (qtcf) ≥ 450 ms (in men) or ≥ 470 ms (in women). * a medical history or complications of clinically significant lung disease (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) * a history of symptomatic congestive heart failure (chf) \[new york heart association (nyha) classes ii to iv\] or serious cardiac arrhythmia requiring treatment * a history of myocardial infarction or unstable angina within 6 months before enrollment * an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals

Keywords: advanced solid tumors asian subjects developmental phase i